Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Edwards v. CoreValve

This article was originally published in The Gray Sheet

Executive Summary

Edwards Lifesciences files transcatheter heart valve patent suit against competitor CoreValve in the District Court of Dusseldorf, Germany May 10. Edwards, developer of the Sapien transcatheter aortic valve, says it has an exclusive sublicense to the patent in question from Johnson & Johnson/Heartport. Edwards, which anticipates European commercialization of Sapien by year-end, is discussing a possible licensing arrangement with CoreValve, which had hoped to launch its ReValving transcatheter aortic valve in Europe in early 2007. Edwards recently received FDA go-ahead to begin a trial to support approval of its device in the United States (1"The Gray Sheet" March 26, 2007, p. 10)...
Advertisement

Related Content

CoreValve gets CE mark
Edwards Set To Launch “Two-Trials-In-One” For Sapien Percutaneous Valve
Edwards Set To Launch “Two-Trials-In-One” For Sapien Percutaneous Valve
Advertisement
UsernamePublicRestriction

Register

MT024787

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel